Abstract :
Acute lymphoblastic leukemia (ALL) is the highly usual childhood tumor. Survivin is a rare organ of the
inhibitor of apoptosis protein family. Survivin was defined in different tumors and found to relate with lowly
prognosis in a variation of cancers counting hematologic malignancies. The purpose of our study was to identify the
prognostic importance of serum survivin levels in children with acute lymphoblastic leukemia. Our study included
24 children (15males, 9females) newly diagnosed who have acute lymphoblastic leukemia. Serum survivin levels
were assayed by quantitative sandwich enzyme immunoassay (ELISA) before any therapy and at day 35 of induction
therapy. Our results have presented an important decrease of serum survivin levels were observed in ALL patients
after therapy (330 ± 221 pg/L) than in the same ALL patients before therapy (467.1 ± 246 pg/L). Our study proposes
that we may use serum level of survivin as a marker of response to therapy in children with acute lymphoblastic
leukemia.
Keyword :
Acute Lymphoblastic Leukemia, Survivin, ELISA, Therapy.